Prosthetic joint infection
Prosthetic joint infection (PJI) is one of the most feared complications of hip and knee arthroplasty, and Staphylococcus aureus, including methicillin-resistant (MRSA) strains, is the leading culprit. The bacteria form dense biofilms on the implant surface that shield them from antibiotics and the immune system, so even prolonged combination antibiotics plus aggressive surgery (DAIR or one/two-stage revision) frequently fail. Lytic bacteriophages are well suited here because they actively replicate at the infection site, penetrate and degrade biofilm, and kill antibiotic-tolerant and multidrug-resistant cells through mechanisms entirely independent of antibiotic resistance. Their exquisite strain specificity also spares the surrounding microbiome and the patient, making them an attractive adjunct delivered directly into the joint during surgery.
How phages act here
Mechanism
Anti-S. aureus phages bind specific surface receptors (e.g., wall teichoic acid and related cell-wall components), inject their genome, hijack the host, and lyse the cell, releasing progeny that amplify the dose in situ ("auto-dosing"). Because killing is receptor-mediated rather than dependent on metabolic targets, phages remain active against MRSA, persister cells, and slow-growing biofilm-embedded bacteria; phage-encoded depolymerases and endolysins help erode the biofilm matrix. Strain specificity is a double-edged sword, requiring susceptibility matching of each patient's isolate, which is why cocktails of two or more phages (e.g., BP13+J1P3, or PP1493+PP1815) are used to broaden coverage and suppress resistance. Critically, phages show synergy with antistaphylococcal antibiotics: in a controlled rat PJI model, phage plus vancomycin produced a 22.5-fold drop in S. aureus burden versus roughly 5-6 fold for either agent alone. Engineered and CRISPR-armed phages targeting S. aureus are in earlier preclinical development to enhance host range and biofilm killing.
Where it stands
Current evidence
As of 2026 the human evidence remains early-stage: solid preclinical and in vitro biofilm/synergy data, multiple published case reports of salvage success, and the first registered controlled trials now launching. Documented compassionate-use cases include a UCSD-treated MSSA prosthetic knee (Ramirez-Sanchez/Aslam, 2021, using Adaptive Phage Therapeutics' phages) and a recalcitrant MRSA prosthetic knee "Salphage" case at Maryland/Yale (Doub, 2022), both with intravenous plus intra-articular phages and generally mild adverse events (notably transient transaminitis and possible serum neutralization on prolonged dosing). On the trial front, the University of Calgary opened NCT06456424, a single-patient Phase I/II MSSA PJI study (intra-articular + 14-day IV cocktail BP13/J1P3; active, not recruiting, started Nov 2024). The most significant development is the industry-sponsored GLORIA trial (NCT06605651, Phagenix), a Phase II multicenter, randomized, double-blind, placebo-controlled study of intra-articular phages PP1493/PP1815 during DAIR in 100 hip/knee S. aureus PJI patients, expected to start in 2026 — building on the French "PhagoDAIR" concept pioneered by Ferry and colleagues in Lyon. Structured registries and programs (PHAGEFORCE/UZ Leuven in Belgium; PHAGEinLYON in France) are prospectively collecting outcomes.
Evidence confidence: medium
The data
Key studies & trials
- Ramirez-Sanchez C, Gonzales F, Buckley M, Biswas B, Henry M, Deschenes MV, Horne B, Fackler J, Brownstein MJ, Schooley RT, Aslam S. Successful Treatment of Staphylococcus aureus Prosthetic Joint Infection with Bacteriophage Therapy. Viruses. 2021;13(6):1182. ↗
- Doub JB, Ng VY, Lee M, Chi A, Lee A, Wurstle S, Chan B. Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection. Antibiotics (Basel). 2022;11(5):616. ↗
- Morris JL, Letson HL, Elliott L, Grant AL, Wilkinson M, Hazratwala K, McEwen P. Evaluation of bacteriophage as an adjunct therapy for treatment of peri-prosthetic joint infection caused by Staphylococcus aureus. PLoS One. 2019;14(12):e0226574. ↗
- Phagenix. GLORIA: A Phase II Proof of Concept Multicenter, Randomized, Double-Blind Study to Assess the Safety and Efficacy of Phage Therapy in Patients With Hip or Knee Prosthetic Joint Infection Due to Staphylococcus aureus Treated by DAIR. ClinicalTrials.gov, NCT06605651, 2024-2026. ↗
Who is working on it
Programs & centers
The possibility
If the randomized PhagoDAIR-style trials confirm what the case reports and animal models suggest, phage cocktails could let surgeons rescue an infected implant during a single DAIR washout — sparing patients the morbidity, cost, and disability of staged revision surgery. The vision is a rapid pipeline where a patient's S. aureus isolate is matched to (or banked phages are engineered against) a personalized lytic cocktail within days, delivered intra-articularly alongside antibiotics to dissolve biofilm the drugs cannot reach. Combined with CRISPR-armed and host-range-expanded phages, this could turn one of orthopedics' most intractable, antibiotic-defying infections into a treatable, implant-sparing condition.